You are not logged in.
Openly accessible

Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine

Xiang, Dongxi, Shigdar, Sarah, Qiao, Greg, Wang, Tao, Kouzani, Abbas Z., Zhou, Shu-Feng, Kong, Lingxue, Li, Yong, Pu,Chuwen and Duan, Wei 2015, Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine, Theranostics, vol. 5, no. 1, pp. 23-42, doi: 10.7150/thno.10202.

Attached Files
Name Description MIMEType Size Downloads
xiang-nucleicacidaptamer-2015.pdf Published version application/pdf 17.24MB 186

Title Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine
Author(s) Xiang, Dongxi
Shigdar, Sarah
Qiao, Greg
Wang, Tao
Kouzani, Abbas Z.ORCID iD for Kouzani, Abbas Z. orcid.org/0000-0002-6292-1214
Zhou, Shu-Feng
Kong, LingxueORCID iD for Kong, Lingxue orcid.org/0000-0001-6219-3897
Li, Yong
Pu,Chuwen
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Journal name Theranostics
Volume number 5
Issue number 1
Start page 23
End page 42
Total pages 20
Publisher Ivyspring International
Place of publication Wyoming, N.S.W.
Publication date 2015
ISSN 1838-7640
Keyword(s) active targeting
aptamer
cancer stem cell
cancer theranostic
cancer therapy
chemoresistance
Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Research & Experimental Medicine
CELL ADHESION MOLECULE
MESOPOROUS SILICA NANOPARTICLES
INTERSTITIAL FLUID PRESSURE
ENDOTHELIAL GROWTH-FACTOR
SPONTANEOUS ANIMAL TUMORS
OVARIAN-CARCINOMA CELLS
TARGETED DRUG-DELIVERY
STEM-CELLS
IN-VIVO
BREAST-CANCER
Summary Conventional anticancer therapies, such as chemo- and/or radio-therapy are often unable to completely eradicate cancers due to abnormal tumor microenvironment, as well as increased drug/radiation resistance. More effective therapeutic strategies for overcoming these obstacles are urgently in demand. Aptamers, as chemical antibodies that bind to targets with high affinity and specificity, are a promising new and novel agent for both cancer diagnostic and therapeutic applications. Aptamer-based cancer cell targeting facilitates the development of active targeting in which aptamer-mediated drug delivery could provide promising anticancer outcomes. This review is to update the current progress of aptamer-based cancer diagnosis and aptamer-mediated active targeting for cancer therapy in vivo, exploring the potential of this novel form of targeted cancer therapy.
Language eng
DOI 10.7150/thno.10202
Field of Research 090301 Biomaterials
Socio Economic Objective 860803 Human Pharmaceutical Treatments (e.g. Antibiotics)
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Ivyspring International
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30070168

Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 64 times in TR Web of Science
Scopus Citation Count Cited 67 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 512 Abstract Views, 188 File Downloads  -  Detailed Statistics
Created: Tue, 03 Mar 2015, 09:35:09 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.